Switch to:
Also traded in: Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.21
NYSE:ABBV's Cash to Debt is ranked lower than
83% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NYSE:ABBV: 0.21 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:ABBV' s Cash to Debt Range Over the Past 10 Years
Min: 0.21  Med: 0.63 Max: No Debt
Current: 0.21
Equity to Asset 0.10
NYSE:ABBV's Equity to Asset is ranked lower than
96% of the 722 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NYSE:ABBV: 0.10 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:ABBV' s Equity to Asset Range Over the Past 10 Years
Min: 0.05  Med: 0.13 Max: 0.69
Current: 0.1
0.05
0.69
Interest Coverage 9.73
NYSE:ABBV's Interest Coverage is ranked lower than
73% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 104.15 vs. NYSE:ABBV: 9.73 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:ABBV' s Interest Coverage Range Over the Past 10 Years
Min: 7.95  Med: 55.93 Max: No Debt
Current: 9.73
F-Score: 6
Z-Score: 1.99
M-Score: -2.32
WACC vs ROIC
11.18%
23.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 36.21
NYSE:ABBV's Operating margin (%) is ranked higher than
96% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.25 vs. NYSE:ABBV: 36.21 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:ABBV' s Operating margin (%) Range Over the Past 10 Years
Min: 17.09  Med: 30.16 Max: 36.21
Current: 36.21
17.09
36.21
Net-margin (%) 24.08
NYSE:ABBV's Net-margin (%) is ranked higher than
92% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. NYSE:ABBV: 24.08 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:ABBV' s Net-margin (%) Range Over the Past 10 Years
Min: 8.89  Med: 22.5 Max: 32.62
Current: 24.08
8.89
32.62
ROE (%) 118.92
NYSE:ABBV's ROE (%) is ranked higher than
99% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.55 vs. NYSE:ABBV: 118.92 )
Ranked among companies with meaningful ROE (%) only.
NYSE:ABBV' s ROE (%) Range Over the Past 10 Years
Min: 24.85  Med: 62.95 Max: 180.9
Current: 118.92
24.85
180.9
ROA (%) 10.29
NYSE:ABBV's ROA (%) is ranked higher than
80% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. NYSE:ABBV: 10.29 )
Ranked among companies with meaningful ROA (%) only.
NYSE:ABBV' s ROA (%) Range Over the Past 10 Years
Min: 6.25  Med: 15.79 Max: 39.54
Current: 10.29
6.25
39.54
ROC (Joel Greenblatt) (%) 321.28
NYSE:ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.88 vs. NYSE:ABBV: 321.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:ABBV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 75.1  Med: 144.26 Max: 321.28
Current: 321.28
75.1
321.28
Revenue Growth (3Y)(%) 6.20
NYSE:ABBV's Revenue Growth (3Y)(%) is ranked higher than
52% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. NYSE:ABBV: 6.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:ABBV' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 4.8 Max: 6.2
Current: 6.2
0
6.2
EBITDA Growth (3Y)(%) 4.20
NYSE:ABBV's EBITDA Growth (3Y)(%) is ranked lower than
60% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.60 vs. NYSE:ABBV: 4.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:ABBV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -4.3 Max: 4.2
Current: 4.2
0
4.2
EPS Growth (3Y)(%) -2.20
NYSE:ABBV's EPS Growth (3Y)(%) is ranked lower than
63% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NYSE:ABBV: -2.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:ABBV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -11.3 Max: -1.1
Current: -2.2
» NYSE:ABBV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ABBV Guru Trades in Q4 2015

First Pacific Advisors 75,500 sh (New)
Louis Moore Bacon 36,243 sh (New)
John Paulson 139,700 sh (New)
Joel Greenblatt 204,171 sh (+179.54%)
Murray Stahl 36,019 sh (+2.56%)
Ken Fisher 935,104 sh (+0.77%)
Jeff Auxier 20,272 sh (unchged)
Tom Russo 86,718 sh (unchged)
Dodge & Cox 33,255 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Samuel Isaly 1,225,000 sh (unchged)
First Eagle Investment Sold Out
Mairs and Power 266,811 sh (-0.05%)
Mario Gabelli 40,600 sh (-7.58%)
David Dreman 26,267 sh (-15.80%)
Larry Robbins 13,544,815 sh (-16.24%)
Paul Tudor Jones 32,925 sh (-33.46%)
Pioneer Investments 1,150,074 sh (-49.71%)
NWQ Managers 754,413 sh (-50.59%)
PRIMECAP Management 1,165,045 sh (-53.62%)
Scott Black 40,798 sh (-73.65%)
Jim Simons 582,756 sh (-80.14%)
» More
Q1 2016

ABBV Guru Trades in Q1 2016

Lee Ainslie 43,170 sh (New)
Joel Greenblatt 645,835 sh (+216.32%)
Jim Simons 1,563,056 sh (+168.22%)
David Dreman 30,542 sh (+16.28%)
Pioneer Investments 1,261,434 sh (+9.68%)
NWQ Managers 781,850 sh (+3.64%)
Scott Black 41,959 sh (+2.85%)
Jeff Auxier 20,572 sh (+1.48%)
Larry Robbins 13,686,588 sh (+1.05%)
Mairs and Power 268,191 sh (+0.52%)
Murray Stahl 36,154 sh (+0.37%)
Robert Bruce 232,915 sh (unchged)
Samuel Isaly 1,225,000 sh (unchged)
Louis Moore Bacon Sold Out
John Paulson Sold Out
Dodge & Cox 33,232 sh (-0.07%)
PRIMECAP Management 1,022,845 sh (-12.21%)
Mario Gabelli 35,460 sh (-12.66%)
Ken Fisher 743,284 sh (-20.51%)
First Pacific Advisors 56,050 sh (-25.76%)
Tom Russo 21,718 sh (-74.96%)
Paul Tudor Jones 4,100 sh (-87.55%)
» More
Q2 2016

ABBV Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 159,258 sh (New)
Stanley Druckenmiller 1,324,920 sh (New)
Joel Greenblatt 905,598 sh (+40.22%)
Lee Ainslie 50,540 sh (+17.07%)
Pioneer Investments 1,281,950 sh (+1.63%)
Jeff Auxier 20,672 sh (+0.49%)
Mairs and Power 269,153 sh (+0.36%)
Dodge & Cox 33,232 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Samuel Isaly 1,225,000 sh (unchged)
First Pacific Advisors Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 35,296 sh (-0.46%)
Murray Stahl 34,755 sh (-3.87%)
PRIMECAP Management 979,845 sh (-4.20%)
Scott Black 40,138 sh (-4.34%)
Ken Fisher 693,394 sh (-6.71%)
Larry Robbins 12,454,488 sh (-9.00%)
Tom Russo 17,106 sh (-21.24%)
Jim Simons 1,217,600 sh (-22.10%)
NWQ Managers 562,288 sh (-28.08%)
David Dreman 15,897 sh (-47.95%)
» More
Q3 2016

ABBV Guru Trades in Q3 2016

Paul Tudor Jones 8,900 sh (New)
Jim Simons 1,918,456 sh (+57.56%)
Murray Stahl 35,056 sh (+0.87%)
Stanley Druckenmiller 1,324,920 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
Tom Russo 17,106 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Jeff Auxier 20,622 sh (-0.24%)
Mairs and Power 266,453 sh (-1.00%)
Manning & Napier Advisors, Inc 157,543 sh (-1.08%)
Ken Fisher 684,042 sh (-1.35%)
Lee Ainslie 49,600 sh (-1.86%)
PRIMECAP Management 953,845 sh (-2.65%)
David Dreman 15,019 sh (-5.52%)
Scott Black 36,748 sh (-8.45%)
Pioneer Investments 1,130,994 sh (-11.78%)
Joel Greenblatt 684,356 sh (-24.43%)
Mario Gabelli 20,196 sh (-42.78%)
Larry Robbins 6,030,141 sh (-51.58%)
NWQ Managers 146,743 sh (-73.90%)
Samuel Isaly 742,955 sh (-39.35%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:BMY, NYSE:SNY, OTCPK:GLAXF, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, NYSE:NVS, OTCPK:ALPMY, NYSE:MRK, OTCPK:OTSKF, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:SNPHY, OTCPK:PTKFY, NYSE:PFE, NAS:GWPH, OTCPK:MAYNF » details
Traded in other countries:ABBV34.Brazil, ABBV.France, 4AB.Germany, ABBV.Mexico, ABBV.Switzerland, 0QCV.UK,
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications.

AbbVie Inc is a research-based biopharmaceutical company incorporated in Delaware on April 10, 2012. The Company is engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products. It develops and markets therapies that address some of the world's complex and serious diseases. It products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. It also has a pipeline of new medicines, including more than 50 compounds or indications in clinical development across such important medical specialties as immunology, virology/liver disease, oncology, neurological diseases and women's health. The Company's products offering includes HUMIRA, IMBRUVICA, VIEKIRA, Creon, Synagis, Lupron, Synthroid, Kaletra, AndroGel, Sevoflurane, Duodopa, Dyslipidemia products, and other products. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from AbbVie-owned distribution centers and public warehouses. The Company faces competition from other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics. The manufacture, marketing, sale, promotion, and distribution of AbbVie's products are subject to comprehensive government regulation.

Ratios

vs
industry
vs
history
P/E(ttm) 16.51
ABBV's P/E(ttm) is ranked higher than
77% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.49 vs. ABBV: 16.51 )
Ranked among companies with meaningful P/E(ttm) only.
ABBV' s P/E(ttm) Range Over the Past 10 Years
Min: 9.85  Med: 19.1 Max: 63.37
Current: 16.51
9.85
63.37
Forward P/E 10.75
ABBV's Forward P/E is ranked higher than
75% of the 63 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.41 vs. ABBV: 10.75 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.51
ABBV's PE(NRI) is ranked higher than
76% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.46 vs. ABBV: 16.51 )
Ranked among companies with meaningful PE(NRI) only.
ABBV' s PE(NRI) Range Over the Past 10 Years
Min: 9.85  Med: 19.1 Max: 63.37
Current: 16.51
9.85
63.37
Price/Owner Earnings (ttm) 17.75
ABBV's Price/Owner Earnings (ttm) is ranked higher than
75% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.53 vs. ABBV: 17.75 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABBV' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.74  Med: 16.36 Max: 61.16
Current: 17.75
13.74
61.16
P/B 15.35
ABBV's P/B is ranked lower than
96% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. ABBV: 15.35 )
Ranked among companies with meaningful P/B only.
ABBV' s P/B Range Over the Past 10 Years
Min: 14.08  Med: 19.96 Max: 76.98
Current: 15.35
14.08
76.98
P/S 3.96
ABBV's P/S is ranked lower than
60% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. ABBV: 3.96 )
Ranked among companies with meaningful P/S only.
ABBV' s P/S Range Over the Past 10 Years
Min: 2.83  Med: 4.24 Max: 5.67
Current: 3.96
2.83
5.67
PFCF 14.35
ABBV's PFCF is ranked higher than
70% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.94 vs. ABBV: 14.35 )
Ranked among companies with meaningful PFCF only.
ABBV' s PFCF Range Over the Past 10 Years
Min: 8.65  Med: 14.36 Max: 38.18
Current: 14.35
8.65
38.18
POCF 13.36
ABBV's POCF is ranked higher than
62% of the 268 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.41 vs. ABBV: 13.36 )
Ranked among companies with meaningful POCF only.
ABBV' s POCF Range Over the Past 10 Years
Min: 8.2  Med: 13.35 Max: 31.6
Current: 13.36
8.2
31.6
EV-to-EBIT 14.91
ABBV's EV-to-EBIT is ranked higher than
70% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.07 vs. ABBV: 14.91 )
Ranked among companies with meaningful EV-to-EBIT only.
ABBV' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.3  Med: 15.7 Max: 42.5
Current: 14.91
10.3
42.5
EV-to-EBITDA 13.24
ABBV's EV-to-EBITDA is ranked higher than
66% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.70 vs. ABBV: 13.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABBV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.6  Med: 13.75 Max: 34.1
Current: 13.24
8.6
34.1
PEG 23.00
ABBV's PEG is ranked lower than
94% of the 279 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. ABBV: 23.00 )
Ranked among companies with meaningful PEG only.
ABBV' s PEG Range Over the Past 10 Years
Min: 2.02  Med: 2.22 Max: 23
Current: 23
2.02
23
Current Ratio 1.79
ABBV's Current Ratio is ranked lower than
61% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. ABBV: 1.79 )
Ranked among companies with meaningful Current Ratio only.
ABBV' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 1.92 Max: 2.82
Current: 1.79
1.22
2.82
Quick Ratio 1.61
ABBV's Quick Ratio is ranked lower than
55% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. ABBV: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
ABBV' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.72 Max: 2.65
Current: 1.61
1.06
2.65
Days Inventory 110.84
ABBV's Days Inventory is ranked higher than
53% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.28 vs. ABBV: 110.84 )
Ranked among companies with meaningful Days Inventory only.
ABBV' s Days Inventory Range Over the Past 10 Years
Min: 35.55  Med: 84.38 Max: 115.3
Current: 110.84
35.55
115.3
Days Sales Outstanding 72.29
ABBV's Days Sales Outstanding is ranked higher than
53% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.78 vs. ABBV: 72.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABBV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.53  Med: 78.6 Max: 93.3
Current: 72.29
71.53
93.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.69
ABBV's Dividend Yield is ranked higher than
86% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. ABBV: 3.69 )
Ranked among companies with meaningful Dividend Yield only.
ABBV' s Dividend Yield Range Over the Past 10 Years
Min: 0.85  Med: 3.01 Max: 3.96
Current: 3.69
0.85
3.96
Dividend Payout 0.60
ABBV's Dividend Payout is ranked higher than
82% of the 386 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. ABBV: 0.60 )
Ranked among companies with meaningful Dividend Payout only.
ABBV' s Dividend Payout Range Over the Past 10 Years
Min: 0.55  Med: 0.64 Max: 1.36
Current: 0.6
0.55
1.36
Forward Dividend Yield 4.33
ABBV's Forward Dividend Yield is ranked higher than
90% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. ABBV: 4.33 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.69
ABBV's Yield on cost (5-Year) is ranked higher than
73% of the 791 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. ABBV: 3.69 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABBV' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.85  Med: 3.01 Max: 3.96
Current: 3.69
0.85
3.96
3-Year Average Share Buyback Ratio -0.70
ABBV's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 435 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.60 vs. ABBV: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABBV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.7  Med: -0.25 Max: 0
Current: -0.7
-0.7
0

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.75
ABBV's Price/Projected FCF is ranked higher than
64% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.77 vs. ABBV: 1.75 )
Ranked among companies with meaningful Price/Projected FCF only.
ABBV' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.71  Med: 1.84 Max: 1.86
Current: 1.75
1.71
1.86
Price/Median PS Value 0.93
ABBV's Price/Median PS Value is ranked higher than
73% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. ABBV: 0.93 )
Ranked among companies with meaningful Price/Median PS Value only.
ABBV' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.69  Med: 0.99 Max: 1.24
Current: 0.93
0.69
1.24
Price/Peter Lynch Fair Value 2.24
ABBV's Price/Peter Lynch Fair Value is ranked lower than
64% of the 142 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.67 vs. ABBV: 2.24 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ABBV' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 2.09  Med: 2.21 Max: 2.32
Current: 2.24
2.09
2.32
Earnings Yield (Greenblatt) (%) 6.77
ABBV's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ABBV: 6.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABBV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 6.4 Max: 9.8
Current: 6.77
2.4
9.8
Forward Rate of Return (Yacktman) (%) 13.24
ABBV's Forward Rate of Return (Yacktman) (%) is ranked higher than
60% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.15 vs. ABBV: 13.24 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABBV' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.7  Med: 13.6 Max: 14.5
Current: 13.24
12.7
14.5

More Statistics

Revenue (TTM) (Mil) $25,242
EPS (TTM) $ 3.70
Beta1.46
Short Percentage of Float2.19%
52-Week Range $50.71 - 68.12
Shares Outstanding (Mil)1,625.10

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 25,684 28,127 30,153 33,157
EPS ($) 4.78 5.45 6.23 7.32
EPS w/o NRI ($) 4.78 5.45 6.23 7.32
EPS Growth Rate
(3Y to 5Y Estimate)
5.73%
Dividends Per Share ($) 2.28 2.52 2.64
» More Articles for NYSE:ABBV

Headlines

Articles On GuruFocus.com
Leukemia Treatment Achieves Promising Results Dec 05 2016 
FDA Orphan Drug Designation for AbbVie's Risankizumab Dec 01 2016 
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016 
Testing of Treatment for Cystic Fibrosis Patients Begins Nov 29 2016 
Enanta Pharmaceuticals Releases Results Nov 22 2016 
Abbvie Ends Development Program With Halozyme Nov 21 2016 
How a 15% Decline Is a Gift to Income Investors Nov 21 2016 
AbbVie: Treatment Cured Chronic HCV Patients Nov 16 2016 
AbbVie's Humira a Step Closer to Approval in Europe Nov 15 2016 
Merck Reports Triple-Combo Results Nov 14 2016 

More From Other Websites
New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL)... Dec 05 2016
Leukemia Treatment Achieves Promising Results Dec 05 2016
Bond Sell-Off Could Be Huge for Stocks: 4 Analyst Top Pick Dividend Stocks to Buy Now Dec 05 2016
AbbVie and Johns Hopkins to Collaborate on Cancer Research Dec 05 2016
AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer... Dec 05 2016
2:14 am AbbVie reports 5-year analysis and long-term RESONATE-2 follow-up; 89% with CLL/SLL achieve... Dec 05 2016
Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two... Dec 04 2016
IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and... Dec 03 2016
[$$] New Tax Rules on Corporate Inversions Face Uncertain Future Dec 03 2016
[$$] Tax Rules on Corporate Inversions Face Uncertain Future Dec 02 2016
Uterine Fibroids Segment May Offer Opportunity for NBIX Dec 02 2016
AbbVie’s Venclexta May Become Promising Multiple Myeloma Therapy Dec 02 2016
Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix Dec 02 2016
Acute Myeloid Leukemia: Growth Opportuny for AbbVie’s Venclexta? Dec 02 2016
Billionaire Larry Robbins Confidently Piles Into CBS, Anthem, As Merger Battles Continue Dec 02 2016
Label Expansion May Boost Venclexta’s Growth Prospects Dec 02 2016
What Do Analysts Recommend for Gilead Sciences Stock? Dec 02 2016
FDA Orphan Drug Designation for AbbVie's Risankizumab Dec 01 2016
OraSure Stock Sets Up For Buy Point On Hep C Contract, Helix Win Dec 01 2016
Is AbbVie Inc (ABBV) A Good Stock To Buy? Dec 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)